Drug Discovery

Transgene, AstraZeneca enter into a collaboration for Invir.IO based armed oncolytic immunotherapies

Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases announces the signing of a collaborative research, option and exclusive license agreement with AstraZeneca to co-develop five armed oncolytic vaccinia virus candidates.

Amgen, Syapse enter precision medicine collaboration in oncology

Amgen, a world leader in biotechnology, and Syapse, a company powering precision medicine insights through its global provider network, announced a precision medicine collaboration in oncology.

Tmunity, UC San Francisco collaborate to advance TCR T cell therapies for pediatric cancers

Tmunity Therapeutics has entered into an exclusive licensing and research collaboration with the University of California San Francisco (UCSF) aimed at advancing novel engineered T Cell Receptor (TCR) therapies for rare and currently incurable pediatric conditions with high mortality rates.

Takeda opens new global research facility in San Diego, US

Japan-based Takeda Pharmaceutical has opened a new 165,000ft² global research facility in San Diego of California, US.

Sandoz enters agreement for proposed trastuzumab biosimilar to treat selected HER2-positive cancer tumors

Sandoz, a Novartis division and a global leader in biosimilars, announced that it has entered into an agreement to commercialize a proposed trastuzumab biosimilar.

AstraZeneca, BenevolentAI join forces for AI-powered drug discovery

AstraZeneca has commenced a long-term collaboration with BenevolentAI to tap into the latter’s artificial intelligence (AI) and machine learning technology to accelerate discovery of new drugs for chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF).

Janssen to deploy Iktos’ AI solution to enhance small molecule drug discovery

French start-up company Iktos has entered into a research collaboration with Janssen Pharmaceutica to deploy its artificial intelligence (AI) technology to help the latter increase speed and efficiency of its small molecule drug discovery.

Aptorum launches Smart Pharma for computational repurposed drug discovery

Hong Kong-based Aptorum Group has established a new subsidiary group called Smart Pharma with a focus on discovering computational repurposed drugs to address orphan and unmet diseases.

FSD Pharma to acquire Prismic Pharmaceuticals

FSD Pharma and Prismic Pharmaceuticals have entered into a securities exchange agreement dated April 22, 2019 pursuant to which FSD Pharma has agreed to acquire all of the outstanding securities of Prismic.